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Summary
Multiple myeloma is associated with significant early morbidity and mor-
tality, with considerable end organ damage often present at diagnosis. The
Tackling EArly Morbidity and Mortality in Multiple Myeloma (TEAMM)
trial was used to evaluate routes to diagnosis in patients with myeloma and
the relationship between diagnostic pathways, time to diagnosis and disease
severity. A total of 915 participants were included in the study. Fifty-one
per cent were diagnosed by direct referral from primary care to haematol-
ogy; 29% were diagnosed via acute services and 20% were referred via
other secondary care specialties. Patients diagnosed via other secondary care
specialties had a longer diagnostic interval (median 120 days vs. 59 days)
without an increase in features of severe disease, suggesting they had a rela-
tively indolent disease. Marked intrahospital delay suggests possible scope
for improvement. A quarter of those diagnosed through acute services
reported >30 days from initial hospital consultation to haematology assess-
ment. Participants diagnosed through acute services had poorer perfor-
mance status (P < 00001) and higher burden of end organ damage
(P < 00001) with no difference in the overall length of diagnostic pathway
compared to those diagnosed by direct referral (median 59 days). This sug-
gests that advanced disease in patients presenting through acute services
predominantly reflects disease aggression.
Keywords: multiple myeloma, diagnostic pathways, diagnostic delay, pri-
mary care, time to diagnosis.
Multiple myeloma is a plasma cell malignancy, with an
annual incidence of 5,600 cases and 3,000 deaths in the
UK.1,2 Patients often have poor performance status at diag-
nosis. This can be due to end organ damage associated with
the disease, including hypercalcaemia, infection, renal
impairment or failure, anaemia and bone disease.3-5
Myeloma is commonly diagnosed in older age, (median age
at diagnosis of 70 years),6where comorbidities are common.
Chronic kidney disease unrelated to myeloma can be seen in
25% of patients7,8 and cardiovascular disease, diabetes and
cerebrovascular disease are frequently present.9,10 There is
significant early mortality after diagnosis, often related to
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infection, renal failure and cardiovascular events, with 10%
of patients dying within 60 days of starting anti-myeloma
treatment.4 Despite recent advances in myeloma treatment
with the use of novel therapies, death from infection remains
high during the first year.11
Early diagnosis is recognised as important in improving
cancer outcomes nationally.12,13 Previous research shows that
patients with myeloma have a prolonged pathway to diagno-
sis. Howell et al. showed a median time from first consulta-
tion to diagnosis of 163 days [interquartile rang (IQR) 84–
306], suggesting many patients have a protracted diagnostic
pathway.14 Delays occur in both the patient interval, from
first symptom onset to first healthcare consultation, and in
the diagnostic interval from first healthcare consultation to
final diagnosis.15-17 Previous research suggests those who
experience a longer pathway before myeloma diagnosis are
more likely to have late stage disease at diagnosis.16,18
Although many patients are diagnosed following referral
from primary care, in the UK 34% of patients present as an
emergency, for example through presentation to Emergency
Medicine in secondary care hospitals. These patients have
high mortality in the first year after diagnosis, with a 12-
month net survival of 617% vs. 875% in those diagnosed
by referral from primary care to haematology services.19
Because of the non-specific nature of the presenting symp-
toms, which include back pain, bone pain and lethargy, there
is also potential for patients to be referred from primary care
to secondary care specialist services other than haematology
if myeloma is not initially suspected.18,20 How these path-
ways relate to delays in diagnosis, particularly in those seeing
other secondary care specialties before referral to haematol-
ogy, has not been fully explored previously.
The Tackling EArly Morbidity and Mortality in Multiple
Myeloma (TEAMM) trial was a supportive care trial and
included a planned assessment of the diagnostic pathways of
patients with multiple myeloma in the UK, and the associa-
tion between route to diagnosis and disease severity.
Methods
The TEAMM trial was a double-blind, placebo-controlled
trial of supportive care, with a primary focus of investigating
levofloxacin prophylaxis for 12 weeks to reduce infection in
patients newly diagnosed with myeloma.21 This study was
conducted at 93 hospitals within the UK (Table S1).
Ethical approval was provided by NHS Research Ethics
Committee West Midlands, Coventry and Warwickshire.
Sponsorship was provided by the University of Birmingham
and University of Warwick.
Eligible patients were recruited between 15 August 2012
and 29 April 29th 2016 (Table S2). Data were collected at
initial trial recruitment regarding pathway to diagnosis, with
analysis of this data planned a priori. This included age, gen-
der, ethnicity, performance status at diagnosis and 6 months
prior (using the Eastern Cooperative Oncology Group
performance status scale),22 radiological evidence of bone
disease and blood test results at diagnosis, including full
blood count, calcium level, creatinine and estimated
glomerular filtration rate. Components of the International
Staging System (ISS) score were documented, allowing calcu-
lation of disease stage.23
End organ damage was assessed through the presence of
hypercalcaemia, renal impairment, anaemia and bone disease
(CRAB features) using the International Myeloma Working
Group (IMWG) criteria for myeloma diagnosis (Table S3).24
Survival at 12 months was recorded. Supplementary ques-
tions were included at recruitment regarding consultation
with healthcare services and symptoms prior to diagnosis.
The first question was ‘With hindsight, what were the first
symptoms that we can now attribute to myeloma and when did
they occur?’. After the first 197 participants this was amended
to ‘When did the patient first notice bodily changes and/or
symptoms that they attribute to the myeloma?’ to ensure agree-
ment with the newly published Aarhus statement.25 The
question included four lines to record the symptoms, plus
date of onset for each line.
The other questions asked were as follows:
1. When did the patient first visit a doctor or nurse at their
local general practice about any of these symptoms or
bodily changes?
2. How many times did the patient consult a doctor or
nurse at their local general practice about any of these
symptoms or bodily changes before they were referred (or
diagnosed, if no GP referral)?
3. When did the patient first visit the hospital [includes
accident and emergency (A&E)]?
4. Which hospital department was the patient first seen in
(includes A&E)?
5. When did the patient first see a haematologist about any
of these symptoms?
Responses were used to categorise the diagnostic pathway,
based on the first hospital department where the patient was
seen, and to measure intervals within the diagnostic pathway.
For the purposes of this study, three pathways were
assessed: (i) diagnosis subsequent to attendance in acute ser-
vices, (ii) direct referral from primary care to haematology,
(iii) referral to haematology via other secondary care spe-
cialty (Fig 1).
Those reporting consultation in the Emergency Depart-
ment, or an acute medical or surgical admissions unit were
classified as diagnosed after attending acute services, this
included those with prior consultation within primary care,
in keeping with definitions used by Public Health England.26
Those reporting haematology services as their first hospital
contact were classified as direct referral to haematology.
Those not diagnosed via the acute pathway or direct pathway
were classified as diagnosed via the other secondary care
pathway if sufficient information was available to determine
which department reviewed the participant.
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Intervals were chosen to align with recommendations from
the Aarhus statement25 and were determined from the dates
provided (Fig 1). Patient intervals compare the date of earli-
est symptom onset and the date of earliest healthcare consul-
tation (in primary or secondary care). Diagnostic intervals
compare the date of first healthcare consultation and haema-
tology consultation. As the date of diagnosis was not pro-
vided, the date of first haematology consultation was used as
a surrogate marker. All dates were collected from patient
recall.
Statistical analyses were performed using IBM SPSS statis-
tics (IBM, Armonk, NY, USA). Mean and standard deviation
are reported for normally distributed variables; median
(IQR) are reported where variables are not normally dis-
tributed. All statistical tests are described in the text, figure
or table legends. A P value of <005 signifies statistical signif-
icance throughout.
Results
Participant characteristics
In total, 977 participants were recruited into the TEAMM
trial. Diagnostic pathways were available for 915 participants;
Fig 1. Possible pathway steps taken by patients during diagnostic pathway, from initial symptom onset to diagnosis and treatment. Intervals as
measured in this study. Arrows show direction of travel & referral.
Diagnostic Pathways and End Organ Damage in Multiple Myeloma
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd 3
the remaining participants had not recorded enough infor-
mation to determine their diagnostic pathway and were
excluded from the study.
Of these 915 participants, 468 (51%) were diagnosed by
direct referral from primary care to haematology, 269 (29%)
were diagnosed via acute services and 178 (20%) were
referred via another secondary care specialty (Table 1).
Table 2 shows the specialties assessing participants in the
‘other secondary care’ pathway. The most common spe-
cialties seeing these participants were trauma and orthopae-
dics, gastroenterology or gastrointestinal/colorectal surgery,
respiratory medicine and renal medicine.
There was no significant difference in the age of partici-
pants presenting via each pathway (Kruskal-Wallis
P = 0052). A higher proportion of those referred directly
from primary care to haematology were female compared to
those seen in acute services (chi square P = 0016). There
was a higher proportion of participants from ethnic back-
grounds other than white British in the acute pathway com-
pared with the direct referral pathway (chi square
P = 0023).
Diagnostic intervals
Overall, the median time from symptom onset to haematol-
ogy review was 70 days (Table 1, Fig S1). Patients diagnosed
via the ‘direct’ pathway had the same total interval as those
diagnosed via the ‘acute’ pathway. Those diagnosed via the
‘other secondary care’ pathway had a significantly longer
pathway than either the direct or acute pathways, with a
median of 120 days from initial symptom onset to haematol-
ogy review (Kruskal-Wallis P < 0001).
The median patient interval was 3 days (IQR 0–54)
(Fig S2). There was no significant difference in the reported
patient interval between the pathways (Kruskal-Wallis
P = 0065).
The median diagnostic interval was 42 days (Fig. S3).
Those diagnosed through ‘other secondary care’ services had
a longer diagnostic interval than those diagnosed via the
acute or direct pathways (Kruskal-Wallis P < 0001).
Intrahospital delay, from first secondary care consultation
to haematology review, was assessed (Fig S4). Those diag-
nosed via ‘other secondary care’ services had a longer intra-
hospital delay than those diagnosed via the ‘acute’ pathway
(Kruskal-Wallis P < 0001).
Primary care consultation in participants diagnosed
through acute services
Of those diagnosed via acute services, 195 participants
(725%) had been seen in primary care prior to, or the same
day as, attending acute services. The median length of time
from primary care consultation to acute services presentation
was 18 days (IQR 0–78). Fifty participants (256%) were seen
in primary care the same day that they attended acute
services. There was no difference in age, gender or ethnicity
comparing those who had seen primary care previously and
those who had not (age, Mann-Whitney U P = 008; gender,
chi square P = 082; ethnicity, chi square P = 034).
Markers of severity and end organ damage
At diagnosis, 102% of patients did not have end organ dam-
age as defined by IMWG criteria.
Comparing by diagnostic pathway, there was no signifi-
cant difference in the proportion of patients with hypercal-
caemia (chi square P = 018). There was a higher rate of
renal impairment in those presenting via acute or ‘other sec-
ondary care’ pathways compared with those presenting
through the direct pathway (chi square P < 0001). There
was also a higher rate of anaemia in the acute pathway par-
ticipants compared with the direct pathway (chi square
P < 0001), but no difference in those seen in ‘other sec-
ondary care’ compared to the other pathways. Bone disease
was more common in those diagnosed via the acute pathway
compared to the direct pathway or ‘other secondary care’
pathway (chi square P < 0001).
Table 1 shows the performance status, ISS and CRAB fea-
tures reported per participant in each pathway. Patients pre-
senting via acute pathways were more likely to have two or
more CRAB features present at diagnosis (chi square
P < 0001).
Those attending via acute pathways were more likely to
have a worse ISS than those presenting via the direct pathway
or ‘other secondary care’ pathway (chi square P < 0001).
They were also more likely to have a performance status of
grade 3 or 4 at diagnosis (chi square P < 0001). There was no
difference in the reported performance status at 6 months
prior to diagnosis between each pathway (chi square
P = 066). Those diagnosed via acute pathways were more
likely to have a deterioration in performance status of more
than one grade from 6 months prior to diagnosis to first
haematology consultation (chi square P < 0001).
Survival
Twelve-month survival was 92% for those diagnosed via the
direct pathway, 91% for those diagnosed through acute ser-
vices and 86% for those diagnosed through ‘other secondary
care’ services. There was no difference in overall survival at
12 months from diagnosis between the pathways (logrank
P = 007).
Discussion
This study represents the most comprehensive analysis of
diagnostic pathways in multiple myeloma to date, providing
unique data on pathways within secondary care and the rela-
tionship between end organ damage and diagnostic pathway
intervals for each route to diagnosis.
C. Atkin et al.
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Table 1. Comparison of participants seen via each diagnostic pathway.
Overall
(n = 915)
Direct pathway
51% of participants
(n = 468)
Acute pathway
29% of participants
(n = 269)
Other secondary care pathway
20% of participants
(n = 178)
N % N % N % N %
Age (years) Median 67 68 67 66 P = 0.052
Under 40 10 1.1% 4 0.9% 3 1.1% 3 1.7%
40–49 59 6.4% 20 4.3% 24 8.9% 15 8.4%
50–59 157 17.2% 75 16.0% 49 18.2% 33 18.5%
60–69 329 36.0% 177 37.8% 86 32.0% 66 37.1%
70–79 255 27.9% 137 29.3% 73 27.1% 45 25.3%
80+ 104 11.4% 55 11.8% 33 12.3% 16 9.0%
Gender Male 571 62.4% 271 57.9% 181 67.3% 119 66.9% P = 0.016
Ethnicity White British 803 87.8% 419 89.7% 224 83.2% 160 89.9% P = 0.023
Diagnostic pathway intervals (measured in days)
Total interval:
1st symptom to
haematology review
Median (IQR) 70 (29–174)
(N = 836)
59 (25–161)
(N = 423)
59 (19–138)
(N = 239)
120 (69–268)
(N = 174)
P < 0.001
Patient interval:
1st symptom to first
consultation
Median (IQR) 3 (0–54)
(N = 732)
6 (0–59)
(N = 352)
0 (0–37)
(N = 239)
8 (0–71)
(N = 141)
P = 0.065
Diagnostic interval:
first consultation to
haematology review
Median (IQR) 42 (15–113)
(N = 803)
33 (13–88)
(N = 384)
35 (8–100)
(N = 265)
102 (47–181)
(N = 155)
P < 0.001
Intra-hospital
interval:
1st hospital visit to
haematology review
Median (IQR) N/A N/A 9 (2–30)
(N = 262)
30 (9–60)
(N = 173)
P < 0.001
CRAB features
N % N % N % N %
Hypercalcaemia Yes 42 5.8% 18 5.1% 19 8.1% 5 3.9% P = 0.18
No 676 94.2% 336 94.9% 216 91.9% 124 96.1%
Unknown 197 114 34 49
Renal impairment Yes 78 10.6% 18 4.9% 45 18.8% 15 11.4% P < 0.001
No 660 89.4% 349 95.1% 194 81.2% 117 88.6%
Unknown 177 101 30 46
Anaemia Yes 377 51.0% 159 43.4% 151 62.9% 67 50.4% P < 0.001
No 362 49.0% 207 56.6% 89 37.1% 66 49.6%
Unknown 176 102 29 45
Bone disease Yes 649 71.3% 311 66.6% 219 82.6% 119 66.9% P < 0.001
No 261 28.7% 156 33.4% 46 17.4% 59 33.1%
Unknown 5 1 4 0
Markers of severity
N % N % N % N %
CRAB features
present
0 71 10.0% 51 14.5% 7 3.1% 13 10.1% P < 0.001
1 355 50.0% 195 55.4% 88 38.4% 72 55.8%
≥2 284 40.0% 106 30.1% 134 58.5% 44 34.1%
Unknown 205 116 40 49
ISS 1 206 26.6% 117 29.8% 42 19.0% 47 29.2% P < 0.001
2 341 44.0% 193 49.1% 87 39.4% 61 37.9%
3 228 29.4% 83 21.1% 92 41.6% 53 32.9%
Unknown 140 75 48 17
ECOG performance
status at
randomisation
0–2 836 93.0% 439 96.3% 231 86.8% 166 93.8% P < 0.001
3–4 63 7.0% 17 3.7% 35 13.2% 11 6.2%
Unknown 16 12 3 1
Diagnostic Pathways and End Organ Damage in Multiple Myeloma
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd 5
In this large cohort, most patients were referred from their
general practitioner directly to haematology, while 29% were
diagnosed through acute services, and 20% were referred
from their GP to a secondary care specialty other than
haematology, seeing a wide range of medical and surgical
specialties.
Those seen by acute services had poorer performance sta-
tus, worse disease staging and more features of end organ
damage at diagnosis, and higher rates of deterioration in per-
formance status over the preceding 6 months. However,
there was no difference in the total time interval, from symp-
tom onset to diagnosis, in those diagnosed via acute services
compared to those diagnosed via direct referral from primary
care to haematology, or in the initial performance status 6
months prior to diagnosis. This suggests that poorer progno-
sis in patients diagnosed through acute services is not due to
poorer baseline performance status in these patients. It may
reflect aggressiveness of disease, rather than delays in the
diagnostic process, as they develop a more advanced disease
within the same timeframe.
Three quarters of patients diagnosed via the acute pathway
had consulted primary care prior to assessment in acute ser-
vices. Patients’ symptoms may worsen following initial review
necessitating emergency presentation, or patients with severe
symptoms requiring urgent management may self-present to
primary care but require immediate referral to acute services
when severe illness is recognised. This does not equate to a
failing primary care process, but to correct usage of the sys-
tem, with primary care teams able to recognise and refer the
most unwell patients to secondary care acute services.
Those referred to a non-haematology secondary care spe-
cialty had a significantly longer pathway to diagnosis, due to
an increased diagnostic interval, between first consultation
and haematology review. This is likely to reflect a doubled
administrative and waiting time produced by referral to two
specialties sequentially. Despite this longer pathway, patients
had a similar performance status and ISS score to those
referred directly to haematology, and fewer features of end
organ damage than those diagnosed via acute services. This
suggests patients diagnosed through this pathway may have
relatively indolent disease, as a longer diagnostic course was
not associated with more advanced disease. As the disease is
less aggressive, it may have presented with less classic features
and, therefore, have been more difficult to recognise as mye-
loma, explaining why these patients were referred to other
specialties. Many of these other specialties are those expected
to recognise and manage the complications of myeloma, for
instance orthopaedics may identify those with bone disease,
or renal medicine identify myeloma-related renal disease.
This long pathway may, however, negatively impact patient
experience.
Although differences in rates of end organ damage at diag-
nosis and prognostic features have been noted before in
those diagnosed via different pathways,20 this has not previ-
ously been compared to diagnostic pathway intervals for each
route to diagnosis.
This study did have some limitations. The definition of
acute diagnosis used here differed from that used in Routes
to Diagnosis, as data were not available regarding urgency of
outpatient referral. Subsequently, emergency outpatient refer-
rals were not classified as acute diagnoses within TEAMM. In
this cohort, 29% were diagnosed through acute services,
compared to 34% nationally as described in Routes to Diag-
nosis.26
Table 1. (Continued)
Overall
(n = 915)
Direct pathway
51% of participants
(n = 468)
Acute pathway
29% of participants
(n = 269)
Other secondary care pathway
20% of participants
(n = 178)
N % N % N % N %
ECOG performance
status 6 months
before
randomisation
0–2 871 98.6% 441 98.9% 257 98.1% 173 98.9% P = 0.66
3–4 12 1.4% 5 1.1% 5 1.9% 2 1.1%
Unknown 32 22 7 3
ECOG performance
status deterioration
of more than one
grade
Yes 112 12.7% 30 6.7% 65 24.8% 17 9.7% P < 0.001
No 770 87.3% 415 93.3% 197 75.2% 158 90.3%
Unknown 33 23 7 3
Data shown for the 915 participants where a diagnostic pathway could be determined. The intrahospital interval is not displayed here for total
participants or direct pathway as this is not applicable to the direct pathway. Range for total interval was 0–3810 days for the direct pathway, 0–
5777 days for the acute pathway and 0–5358 for the other secondary care pathway.
Gender: P = 0016 for direct pathway versus acute and other secondary care pathways; ethnicity: P = 0023 for proportion of patients who were
not white British in acute pathway versus direct pathway. Renal impairment: P < 0001 for acute pathway versus direct pathway and for other sec-
ondary care versus direct pathway; anaemia: P < 0001 for acute versus direct pathway; bone disease: P < 0001 for acute versus direct pathway
and acute versus other secondary care pathway. IQR, interquartile range.
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The diagnostic intervals described here are shorter than pre-
viously reported. The median time from symptom onset to
haematology review was 70 days, which is shorter than the
156 days reported by Neal et al.27 and the 163 days reported
by Howell et al.14 This may reflect the cohort of patients
recruited to TEAMM, who were relatively young compared to
those with myeloma overall, with a relatively good perfor-
mance status.6 This may reflect the TEAMM study protocol,
which required participants to keep a patient diary, and collect
nasal swabs and stool samples over 4 months. Patients who
were more unwell may have found this too taxing. Also, those
not planned for active treatment were excluded. If those with
very long pathways were too unwell to participate, the length
of the diagnostic pathway may have been underestimated.
Similarly, patients who died before the diagnosis was con-
firmed or treatment initiated would not be included and,
therefore we cannot comment on the diagnostic pathways
taken by this subgroup of patients.
This shorter interval may also relate to the definition of
date of diagnosis used here. Date of haematology consulta-
tion provided a surrogate for date of diagnosis, and although
this is a recognised method of defining the date of diagno-
sis,25 the date of histological diagnosis is likely to be later,
leading to longer pathway intervals. In addition, diagnostic
pathway intervals were based on patient recall, which is
prone to time interval underestimation.28 The pathway
length reported here is, therefore, likely to be an underesti-
mate. As all pathways were assessed using this method, and
there is unlikely to be any effect of pathway on time from
haematology consultation to histological diagnosis, compar-
isons between the pathways remain valid.
This study uses severity markers including staging, perfor-
mance status and end organ damage to compare the diagnostic
pathways. End organ damage may have been underestimated
as this was based on results at trial recruitment, where hyper-
calcaemia, anaemia or severe acute kidney injury may have
already been treated. There was no difference in survival at
12 months between the pathways in this study. As survival is
known to vary by pathway to diagnosis, with poorer survival
in those presenting through acute services,20,26 this may again
reflect that this cohort were comparatively well compared to
the overall myeloma patient population, and those diagnosed
through acute services with advanced organ damage causing
severe symptoms may be less likely to be recruited into trials.
These findings should be further explored in a wider cohort of
patients diagnosed through acute services.
Although these findings did not suggest longer diagnostic
pathways in those diagnosed via acute services, many of these
patients still experienced delays before haematology review,
with 25% reporting over 30 days from initial hospital atten-
dance to haematology consultation. Further research is
needed in this subgroup of patients to explore the causes of
this delay and implement strategies for improvement, such as
robust follow-up pathways of laboratory investigations.
Strategies to improve survival in those diagnosed through
acute services focussed solely on reducing the length of the
diagnostic pathway may have only limited effect. The diag-
nostic pathway is no longer in those diagnosed through acute
services than in those diagnosed through direct referral to
haematology from primary care; therefore, poorer prognosis
in these patients is unlikely to be entirely attributable to
delays in diagnosis. Diagnosis through acute services may be
unavoidable for some with aggressive disease. This has signifi-
cant implications for early diagnosis programmes, and strate-
gies that are not reliant on early identification of symptoms
need to be explored, such as targeted screening.
Conclusion
Delay in diagnosis remains a major problem in multiple
myeloma. Patients are diagnosed through multiple pathways,
Table 2. Secondary care specialties where participants were seen in
‘other secondary care’ pathway.
Secondary care specialty
Number
of
participants
Percentage
of those in
other
secondary
care
pathway
(n = 178)
Percentage
overall
(n = 915)
Orthopaedics 35 197 38
Gastroenterology &
GI surgery
29 163 32
Respiratory 21 118 23
Renal medicine 19 107 21
Oncology 16 9 17
Rheumatology 9 51 1
Urology 9 51 1
General medicine 8 45 09
Neurology &
neurosurgery
7 39 08
Cardiology 6 34 07
ENT surgery 5 28 05
GI surgery 4 22 04
Geriatrics 3 17 03
Endocrinology 3 17 03
General surgery 3 17 03
Cardiothoracic surgery 1 06 01
Dermatology 1 06 01
Gynaecology 1 06 01
Ophthalmology 1 06 01
Pain clinic 1 06 01%
Table shows the number of participants reporting these speciality as
first hospital department contact, the percentage of those in the
‘other secondary care’ pathway seeing this specialty (out of 178 par-
ticipants), and the percentage of participants overall reporting seeing
this specialty (of the 915 participants where pathway to diagnosis
could be determined). ENT, Ear, Nose and Throat surgery; GI, gas-
trointestinal.
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with route to diagnosis linked to aggressiveness of disease.
Those diagnosed through acute services do not experience a
longer diagnostic pathway but have a poorer performance
status and higher burden of end organ damage, probably
reflecting more aggressive disease.
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Fig S1. Total interval by pathway to diagnosis. Cumulative
histogram showing the time in days from first symptom
onset to haematology review for patients seen via each path-
way, for those with intervals up to 730 days.
Fig S2. Patient interval by pathway to diagnosis. Cumula-
tive histogram showing the time in days from first symptom
onset to haematology review for patients seen via each path-
way, for those with intervals up to 365 days.
Fig S3. Diagnostic interval by pathway to diagnosis.
Cumulative histogram showing the time in days from first
symptom onset to haematology review for patients seen via
each pathway, for those with intervals up to 365 days.
Fig S4. Intrahospital interval by pathway to diagnosis.
Cumulative histogram showing the time in days from first
symptom onset to haematology review for patients seen via
each pathway, for those with intervals up to 365 days.
Table S1. Inclusion and exclusion criteria of the TEAMM
trial.
Table S2. Features of end organ damage in multiple mye-
loma.
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